Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olof Selroos

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Therapeutics and Clinical Risk Management|March 25, 2008
A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroidOlof Selroos
Respiratory Medicine|April 5, 2008
Effect of disease duration on dose-response of inhaled budesonide in asthmaOlof Selroos
Current Medical Research and Opinion|October 7, 2004
The place of inhaled corticosteroids in chronic obstructive pulmonary diseaseOlof Selroos
Therapeutic Delivery|December 18, 2013
Dry-powder inhalers in acute asthmaOlof Selroos
Pharmaceuticals (Basel, Switzerland)|April 27, 2024
Budesonide Attains Its Wide Clinical Profile by Alternative KineticsRalph Brattsand, Olof Selroos
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|September 24, 2024
Inhaled budesonide and pulmonary sarcoidosis revisitedOlof Selroos, Ralph Brattsand
Pulmonary Pharmacology & Therapeutics|July 2, 2002
Formoterol Turbuhaler 4.5 microg (delivered dose) has a rapid onset and 12-h duration of bronchodilationOlof Selroos, Tommy Ekström
Pulmonary Pharmacology & Therapeutics|September 30, 2022
May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?Ralph Brattsand, Olof Selroos
Therapeutic Advances in Respiratory Disease|May 16, 2009
Use of dry powder inhalers in acute exacerbations of asthma and COPDOlof Selroos, Lars Borgström, Jarl Ingelf
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 12, 2005
Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanationOlof Selroos, Staffan Edsbäcker, Christer Hultquist
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Therapeutics and Clinical Risk Management|March 25, 2008
A smarter way to manage asthma with a combination of a long-acting beta(2)-agonist and inhaled corticosteroidOlof Selroos
Respiratory Medicine|April 5, 2008
Effect of disease duration on dose-response of inhaled budesonide in asthmaOlof Selroos
Current Medical Research and Opinion|October 7, 2004
The place of inhaled corticosteroids in chronic obstructive pulmonary diseaseOlof Selroos
Therapeutic Delivery|December 18, 2013
Dry-powder inhalers in acute asthmaOlof Selroos
Pharmaceuticals (Basel, Switzerland)|April 27, 2024
Budesonide Attains Its Wide Clinical Profile by Alternative KineticsRalph Brattsand, Olof Selroos
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|September 24, 2024
Inhaled budesonide and pulmonary sarcoidosis revisitedOlof Selroos, Ralph Brattsand
Pulmonary Pharmacology & Therapeutics|July 2, 2002
Formoterol Turbuhaler 4.5 microg (delivered dose) has a rapid onset and 12-h duration of bronchodilationOlof Selroos, Tommy Ekström
Pulmonary Pharmacology & Therapeutics|September 30, 2022
May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?Ralph Brattsand, Olof Selroos
Therapeutic Advances in Respiratory Disease|May 16, 2009
Use of dry powder inhalers in acute exacerbations of asthma and COPDOlof Selroos, Lars Borgström, Jarl Ingelf
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 12, 2005
Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanationOlof Selroos, Staffan Edsbäcker, Christer Hultquist
Pageof 4